The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

Medicare's decision to reimburse for the G6 and G7 is a favorable development for Dexcom ... without confirming the blood glucose levels with a traditional meter. Further, the emergence of ...

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage ...

Shares traded 8.5% higher at $72.55. The company, which focuses on glucose biosensing--which measures glucose levels in wearers--said that the Food and Drug Administration has cleared the Dexcom G7 15 ...

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

The integration of its glucose monitoring technology ... several issues with its popular G6 & G7 sensor manufacturing. The company response is inadequate. DexCom (NasdaqGS:DXCM) witnessed a ...

Select continuous glucose monitoring systems, such as Dexcom G7 and Dexcom G6, are equipped with a predictive Urgent Low Soon alert that can warn users up to 20 minutes in advance of a severe ...